| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant (NCT03537599) | Sumithira Vasu | 2020-01-10 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984) | University of Southern California | 2018-05-09 |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia (NCT02791919) | National Cancer Institute (NCI) | 2017-05-25 |
| WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02666950) | Mayo Clinic | 2017-05-05 |
| Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia (NCT02581917) | Wake Forest University Health Sciences | 2017-04-21 |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent (NCT03146871) | University of Southern California | 2017-04-20 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820) | Mayo Clinic | 2017-04-04 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS (NCT02921061) | Fred Hutchinson Cancer Center | 2016-11-17 |
| Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02635074) | Steven E. Coutre | 2016-11-01 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT (NCT02728700) | Stanford University | 2016-02-01 |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (NCT02323607) | Bhavana Bhatnagar | 2016-01-12 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT02159495) | City of Hope Medical Center | 2015-12-15 |
| Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia (NCT02583893) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-10-07 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (NCT02484391) | Wake Forest University Health Sciences | 2015-09-01 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548) | National Cancer Institute (NCI) | 2015-08-18 |
| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT02122081) | Sumithira Vasu | 2015-07-27 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT02446964) | City of Hope Medical Center | 2015-06-25 |
| Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02337478) | Wake Forest University Health Sciences | 2015-06-05 |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02299518) | Alice Mims | 2015-05-18 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02316964) | Sumithira Vasu | 2015-04-21 |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (NCT01849276) | Northwestern University | 2015-03-11 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (NCT02333162) | University of Chicago | 2014-12-05 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02049801) | Bruno C. Medeiros | 2014-12-01 |
| Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (NCT02353143) | Menarini Group | 2014-12-01 |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT02070458) | Case Comprehensive Cancer Center | 2014-10-08 |
| A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02204085) | Beth Israel Deaconess Medical Center | 2014-09-01 |
| Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01787474) | M.D. Anderson Cancer Center | 2014-05-19 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML (NCT02094794) | City of Hope Medical Center | 2014-05-12 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (NCT02129101) | Mayo Clinic | 2014-05-01 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children (NCT01858740) | Fred Hutchinson Cancer Center | 2014-04-10 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02030405) | Steven E. Coutre | 2014-03-01 |
| CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02019069) | Rondeep Brar | 2014-02-03 |
| AML Therapy With Irradiated Allogeneic Cells (NCT02105116) | Rutgers, The State University of New Jersey | 2014-02-01 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01904643) | Stanford University | 2014-02-01 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT02044796) | Fred Hutchinson Cancer Center | 2014-01-23 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (NCT01907815) | National Cancer Institute (NCI) | 2013-10-01 |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (NCT01798901) | Alison Walker | 2013-09-17 |
| Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01876953) | City of Hope Medical Center | 2013-09-13 |
| Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy (NCT01869114) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-07-08 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01707004) | University of Wisconsin, Madison | 2013-05-16 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01664897) | M.D. Anderson Cancer Center | 2013-05-16 |
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (NCT01870596) | National Cancer Institute (NCI) | 2013-05-01 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01835288) | Stanford University | 2013-05-01 |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01820624) | Paolo Caimi, MD | 2013-04-30 |
| PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant (NCT01841333) | University of Colorado, Denver | 2013-04-29 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (NCT01801046) | University of Southern California | 2013-03-06 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01768897) | Wake Forest University Health Sciences | 2013-01-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT01729845) | Fred Hutchinson Cancer Center | 2012-12-20 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01757639) | National Cancer Institute (NCI) | 2012-12-14 |
| Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation (NCT01758367) | Chinese PLA General Hospital | 2012-12-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT01519596) | Wake Forest University Health Sciences | 2012-10-01 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies (NCT01527045) | Fred Hutchinson Cancer Center | 2012-09-25 |
| Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (NCT01607645) | Fred Hutchinson Cancer Center | 2012-07-01 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01839240) | University of Chicago | 2012-06-06 |
| Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (NCT01548911) | Wake Forest University Health Sciences | 2012-05-01 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT01550185) | Roswell Park Cancer Institute | 2012-05-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS (NCT01300572) | Fred Hutchinson Cancer Center | 2012-01-01 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (NCT01555268) | Roswell Park Cancer Institute | 2011-10-31 |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (NCT01564277) | Roswell Park Cancer Institute | 2011-09-29 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881) | Fred Hutchinson Cancer Center | 2011-09-01 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01342887) | Fred Hutchinson Cancer Center | 2011-04-01 |
| Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01246622) | Roswell Park Cancer Institute | 2011-02-07 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (NCT01260714) | National Cancer Institute (NCI) | 2010-12-01 |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy (NCT01235572) | Fred Hutchinson Cancer Center | 2010-12-01 |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01253447) | National Cancer Institute (NCI) | 2010-10-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (NCT01174888) | Alison Walker | 2010-08-01 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219) | National Cancer Institute (NCI) | 2010-07-15 |
| Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT01127009) | Case Comprehensive Cancer Center | 2010-07-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia (NCT01139970) | National Cancer Institute (NCI) | 2010-06-04 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (NCT01159301) | National Cancer Institute (NCI) | 2010-06-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (NCT01159028) | Bio-Path Holdings, Inc. | 2010-06-01 |
| Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01130506) | National Cancer Institute (NCI) | 2010-05-17 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT01132586) | National Cancer Institute (NCI) | 2010-05-01 |
| Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome (NCT00988715) | Fred Hutchinson Cancer Center | 2010-04-21 |
| Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant (NCT01083706) | Fred Hutchinson Cancer Center | 2010-04-01 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (NCT01044745) | University of Nebraska | 2009-12-10 |
| Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (NCT01031368) | Nohla Therapeutics, Inc. | 2009-12-01 |
| 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01041443) | City of Hope Medical Center | 2009-12-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML (NCT00895934) | National Cancer Institute (NCI) | 2009-05-01 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (NCT00860574) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease (NCT00863434) | University of Washington | 2009-02-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (NCT02144675) | Rutgers, The State University of New Jersey | 2009-01-01 |
| Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS (NCT00839982) | Fred Hutchinson Cancer Center | 2008-11-01 |
| Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00634244) | National Cancer Institute (NCI) | 2008-10-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |